| Popis: |
Zheng Zhao,1 Zhangjun Song,2 Xuwei Wang,3 Haifeng Sun,1 Xiaomin Yang,2 Yong Yuan,4 Pan Yu3 1Third Department of Medical Oncology, Shannxi Provincial Cancer Hospital, 2Breast Surgery Center, Shannxi Provincial Cancer Hospital, Xi’an, 3Marketing Department, Novogene Bioinformatics Institute, Beijing, 4Pathology Department, Shannxi Provincial Cancer Hospital, Xi’an, People’s Republic of China Abstract: ROS1 fusion is a common genetic alteration in non-small-cell lung cancer. Crizotinib, an anaplastic lymphoma kinase inhibitor, shows efficacy in the treatment of lung cancer cases with ROS1 translocation. We report the response to crizotinib of a lung adenocarcinoma patient harboring a novel SLC34A2-ROS1 fusion variant, which was different from the two common SLC34A2-ROS1 fusion types reported in the literature. After crizotinib administration, overall recovery was good in this patient; the primary lesion was successfully treated, the lymph node metastases had disappeared, and the metabolism was normal. Keywords: SLC34A2-ROS1 fusion, crizotinib, lung adenocarcinoma, next-generation sequencing |
